QZQimin Zhan

Qimin Zhan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qimin Zhan has a total of 547 co-authors. Here are the top co-authors by number of shared publications:

  • Yan Wang

    State Key Laboratory of Molecular Oncology Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Laboratory of Molecular Oncology Peking University Cancer Hospital & Institute Beijing China

    52 shared publications
  • Qingnan Wu

    State Key Laboratory of Molecular Oncology Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Laboratory of Molecular Oncology Peking University Cancer Hospital & Institute Beijing China

    28 shared publications
  • Jie Chen

    Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China

    24 shared publications
  • Weimin Zhang

    Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China

    24 shared publications
  • Jiawen Fan

    State Key Laboratory of Molecular Oncology Laboratory of Molecular Oncology Peking University Cancer Hospital & Institute Beijing China

    17 shared publications
  • Jinting Li

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, China

    17 shared publications

Latest Publications

  • Open Access

    Erratum to Flotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway

    by Lianmei Zhao, Jie Li, Yueping Liu, Wei Zhou, Yanan Shan, Xinyi Fan, Xinliang Zhou, Baoen Shan, Yongmei Song, Qimin Zhan

  • Open Access

    Spatiotemporal Multi‐Omic Mapping Reveals Liver‐Muscle Metabolic Crosstalk in Cancer Cachexia

    by Zihan Tian, Qianyu Wang, Wenyan Gao, Xianfeng Li, Jiawen Fan, Xiaoliang Wu, Siqi Liu, Xiangdong Ming, Danna Yeerken, Mutian Shen, et al.

    Tumor and host interaction contributes to cancer cachexia, a systemic wasting syndrome characterized by tissue loss (adipose and skeletal muscle), anorexia, fatigue, and metabolic reprogramming. Nevertheless, the spatio‐temporal molecular dynamics of multiple tissues during cancer cachexia development remain elusive. Here, we present a comprehensive overview of the biological alterations and metabolic reprogramming of cancer cachexia across two species, 25 organs, and 3230 samples, by integrating transcriptomic, proteomic, and metabolomic profiles spanning different cachectic stages and sexual dimorphism. Using this cancer cachexia atlas (CCAtlas), we identified dysregulated tissues of cancer cachexia, including skeletal muscle, liver, and blood. We revealed coordinated metabolic reprogramming across tissues, including dysregulated amino acid metabolism and one‐carbon metabolism. Temporal profiling illustrated dynamic molecular signatures during cancer cachexia progression. The exacerbated inflammatory status in males potentially contributed to a more severe whole‐body wasting phenotype. The liver‐muscle crosstalk potentiated skeletal muscle atrophy through creatine deficiency via hepatic Gamt downregulation in the LLC model. Creatine supplementation and hepatic Gamt overexpression in the LLC model attenuated skeletal muscle wasting. Together, CCAtlas provides fundamental and systemic insights into multi‐omic molecular dynamics and metabolic rewiring of cancer cachexia from the perspective of tumor and/or inter‐organ crosstalk across species.

  • Open Access

    Geospatial genetic evolution and phenotypic plasticity in triple-negative breast cancer

    by Ruoxi Hong, Pin Wu, Yuyue Qiu, Shichen Dong, Yuhan Huang, Kaping Lee, Huifang Wang, Mei Li, Cuijuan Zhang, Feng Ye, et al.

    The interplay between genotype and phenotype in shaping spatial heterogeneity and metastatic evolution in triple-negative breast cancer (TNBC) remains poor

  • Open Access

    The evolving global landscape of first-in-class oncology drug innovation

    by Xiangyun Mao, Zhaoqing Wang, Shu Kong, Yue Yang, Nancy A. Dreyer, Yi Ba, Michael T. Lotze, Qimin Zhan, Guanqiao Li

    First-in-class (FIC) oncology drugs—defined by their novel mechanisms of action or targeting of previously unaddressed molecular targets—have emerged as a leading force in cancer therapeutic innovation. In this Review, we delineate the global landscape of FIC oncology drug approvals between 2009 and 2024 and analyze the evolving characteristics of both approved FIC therapies and potential FIC (PFIC) candidates in clinical development. To clarify the underlying dynamics of this evolution, we construct an analytic framework encompassing four distinct archetypes of FIC development: new targets, new mutation subtypes, new modalities, and new multi-target strategies. This typology enables a systematic dissection of divergent translational trajectories and bottlenecks across the evolving FIC landscape. While most approved FIC drugs are driven by target novelty, PFIC candidates increasingly capitalize on technological breakthroughs, particularly in modalities such as cell and gene therapies, antibody–drug conjugates, proteolysis-targeting chimeras, cancer vaccines and bispecific antibodies. These advances not only expand the boundaries of druggability but also redefine how therapeutic interventions are conceived, delivered and translated into patient outcomes. Despite this momentum, critical bottlenecks—including the identification and validation of tractable targets, high clinical attrition rates, and persistent disparities in global access—continue to limit the real-world impact of oncology innovation. Looking forward, the convergence of artificial intelligence, next-generation modalities, and translational collaboration may serve as powerful engines for translating scientific breakthroughs into widely accessible therapies and for driving sustainable, mechanism-based innovations in oncology.


  • Open Access

    A Retrospective Observational Study of Safety and Effectiveness of Abemaciclib in Chinese Patients with Breast Cancer

    by Fangyuan Zhao, Yaxin Liu, Hanfang Jiang, Liu Yang, Qinyi Zhu, Xiao Ma, Huiping Li, Qimin Zhan

    Introduction Abemaciclib is approved in China for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) and early breast cancer (EBC). This retrospective, real-world observational study evaluated the safety and effectiveness of abemaciclib among Chinese patients with EBC/ABC. Methods The study included patients from the National Anti-Tumor Drug Surveillance System who initiated abemaciclib between April 2021 and December 2022, with ≥ 1 post-treatment visit by June 2023. Primary objectives were to describe patient characteristics and prevalence of adverse events (AEs) of interest. Real-world progression-free survival (rwPFS) and overall survival (OS) among patients with ABC were exploratory objectives. Results Overall, 3423 patients (EBC 619, ABC 2804) were included (3407 [99.5%] female and 16 [0.5%] male); most initiated abemaciclib at 150 mg twice daily (EBC 79.9%, ABC 68.9%). Among patients with EBC, 92.2% had positive lymph nodes. Among patients with ABC, 45.2%, 25.4%, and 29.3% received abemaciclib as first-line, second-line, and third-or-later-line therapy, respectively. Treatment discontinuation occurred in 5.2% of patients with EBC and 25.1% with ABC, and dose reduction in 21.2% and 20.1%, respectively. AEs of interest occurred in 60.7% of patients with EBC and 57.3% with ABC, mostly grades 1–2 in severity; the most common AE of interest was neutropenia (39.9% and 34.5% in patients with EBC and ABC, respectively). Discontinuation due to AEs occurred in 2.4% of patients with EBC and 4.1% with ABC. Among patients with ABC receiving abemaciclib as first-line, second-line, and third-or-later-line therapy, 12-month rwPFS rates were 80.5%, 72.7%, and 57.3%, and OS rates were 90.5%, 84.3%, and 73.0%, respectively. Effectiveness was consistent across menopausal status and endocrine therapy subgroups. Conclusions In this largest real-world study of abemaciclib in China to date, abemaciclib was well tolerated with no new safety signals, and its effectiveness was consistent with prior trials, confirming its positive benefit–risk profile in real-world settings.


  • Open Access

    Halofuginone is a Molecular Glue Degrader of Integrin β 4

    by Wei Gong, Di Yang, Junrui Tian, Yufei Chai, Tiantian Yu, Qingnan Wu, Yan Wang, Weimin Zhang, Qimin Zhan

    Integrin β 4 (gene name: ITGB4) overexpression is associated with aggressive phenotypes and poor prognosis across multiple solid tumors. Despite its clinical significance, therapeutic strategies targeting integrin β 4 remain underdeveloped. Targeted protein degradation technology, particularly molecular glue degraders, offer a promising approach for eliminating oncoproteins. However, the serendipitous discovery of molecular glues and limited exploration of substrate receptor have largely hindered the rational development of molecular glue degraders. In this study, through high throughput screening from a natural product library, we identified halofuginone (HF) as a potential molecular glue that promotes integrin β 4 degradation via the CRL4B WDR18 E3 ubiquitin ligase complex. HF administration markedly disrupted the aggressive progression of tumor cell both in vitro and in vivo. In summary, our study not only establishes HF as a promising degrader of integrin β 4 but also demonstrates the utility of natural product screening for discovering molecular glue degraders, providing a novel therapeutic strategy for targeting oncogenic transmembrane proteins.

  • Open Access

    Targeting DGKα/PA axis inhibits tumor immune evasion and augments sensitivity to immunotherapy in gastrointestinal cancers

    by Jie Chen, Siqi Liu, Ting Peng, Fenglong Wang, Yuheng Zhu, Jingyuan Pang, Qingnan Wu, Yan Wang, Qimin Zhan

    Immune checkpoint inhibitors (ICIs) have shown promising antitumor efficacy in certain types of solid tumors. However, the efficacy of ICIs remains unsatisfactory owing to the dysregulation of signaling pathways in local tumor tissues. Here, we reveal that diacylglycerol kinase α (DGKα)-derived phosphatidic acid (PA) directly binds to nuclear factor-κB (NF-κB) and enhances the transcriptional activity of NF-κB to increase the expression of programmed cell death 1-ligand 1 (PD-L1) and facilitate the immune evasion of tumor cells and orchestrate immune microenvironment. Inhibition of DGKα activity decreases the intratumoral PD-L1 level and induces cytotoxic T lymphocytes (CTLs) infiltration and resultantly enhances the antitumor efficacy of ICIs. Plasma PA can function as a biomarker to evaluate the efficacy of ICIs in gastrointestinal cancers. Overall, our results identify the DGKα/PA axis as a metabolic driver of immune evasion and CTLs exclusion, representing a promising target to enhance ICIs' efficacy in gastrointestinal cancer treatments.


  • Top Cited Papers
    Open Access

    Strain-level genetic heterogeneity and colonization dynamics drive microbiome therapeutic efficacy

    by Kai Chen, Yina Liu, Jie Rong, Ningbin Dai, Caihua Xu, Heng Li, Ling Zhong, Baoyan Wang, Zhen Ji, Shichang Xie, et al.


  • Open Access

    The consensus molecular subtypes of esophageal squamous cell carcinoma

    by Heyang Cui, Zhongxu Zhu, Enwei Xu, Lin Qi, Yikun Cheng, Yinghan Zhang, Ling Zhang, Matthew Yibo Cheng, Bin Yang, Ruifang Sun, et al.

    Esophageal squamous cell carcinoma (ESCC) lacks a standardized classification system, resulting in inconsistent clinical management and a suboptimal prognosis. This study addresses the urgent need for a robust consensus taxonomy to facilitate precision treatment for ESCC. We employed a network-based approach to elucidate the interconnections among eight existing classification systems, leading to the identification of four distinct consensus molecular subtypes (ECMSs): ECMS1-MET (metabolic), characterized by dysregulated metabolic pathways and NFE2L2 activation; ECMS2-CLS (classical), featuring upregulated cell cycle and canonical signaling pathways; ECMS3-IM (immunomodulatory), marked by robust immune activation and elevated PD-1 expression; and ECMS4-MES (mesenchymal), associated with mesenchymal transition, stromal activation, and VEGF signaling. To improve clinical applicability, we developed an image-based framework (imECMS) that utilizes spatial organization features (SOFs) quantified from autodelineated hematoxylin‒eosin (H&E)-stained whole-slide images through deep learning algorithms. The imECMS classifier assigns patients to one of the four ECMS subtypes, which correlate with distinct molecular characteristics, prognoses, and responses to neoadjuvant chemotherapy and immunotherapy. Validation across multiple independent cohorts confirmed that the imECMS accurately classifies ESCC subtypes from histopathological images, offering a robust and effective tool for precision medicine. In summary, the ECMS/imECMS subtyping systems we developed are the most robust frameworks for ESCC to date, providing clear biological insights and a foundation for clinical stratification and targeted therapies.